Actavis has an eye on more deals, for 'couple billion dollars' or so

Actavis CEO Brent Saunders

Actavis ($ACT), still awaiting the close of its $66 billion buyout of Allergan ($AGN), is on the lookout for more bolt-on acquisitions. As CEO Brent Saunders told Bloomberg, the company isn't up for any transformational deals in the short term, instead looking for buyouts in the "couple billion dollar" range. More

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.